Data continue to accumulate indicating that many systematic reviews are methodologically
flawed, biased, redundant, or uninformative. Some improvements have occurred in recent …

Context Considerable advances have been made in the first-line treatment of metastatic
renal cell carcinoma (mRCC), with immunotherapy-based combinations including …

Over the past decade, the management of metastatic renal cell carcinoma (RCC) has
undergone rapid evolution, culminating in a significant improvement in prognosis with …

Introduction: Renal cancer is one of the most common cancers in the world, but the effect of
therapies on advanced renal cancer has not improved for decades. Ferroptosis is an …

Tumor growth, metastasis and therapeutic response are believed to be regulated by the
tumor and its microenvironment (TME) in advanced renal cell carcinoma (RCC). However …

The landscape of prostate cancer care has rapidly evolved. We have transitioned from the
use of conventional imaging, radical surgeries, and single-agent androgen deprivation …

Cancer involves complex etiology factors, multiple stages, and intricate gene mutations.
Long non-coding RNAs (lncRNAs) are implicated as molecular mechanisms underlying …

Background In metastatic clear cell renal cell carcinoma (ccRCC), different combination
therapies, each including anti-PD-1 immune checkpoint blockade (ICB), are applied as first …

Objectives Immune checkpoint blockade (IO) has revolutionised the treatment of metastatic
renal cell carcinoma (mRCC). Early C‐reactive protein (CRP) kinetics, especially the …

Objective To map whether and how systematic reviews (SRs) with network meta-analysis
(NMA) use presentation formats to report (a) structured evidence summaries–here defined …